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Abstract 
FDM 3D printing has been recently attracted increasing research efforts towards the 
production of personalized solid oral formulations. However, commercially available FDM 
printers are extremely limited with regards to the materials that can be processed to few types 
of thermoplastic polymers, which often may not be pharmaceutically approved materials nor 
ideal for optimizing dosage form performance of poor soluble compounds. This study 
explored the use of polymer blends as a formulation strategy to overcome this processability 
issue and to provide adjustable drug release rates from the printed dispersions. Solid 
dispersions of felodipine, the model drug, were successfully fabricated using FDM 3D 
printing with polymer blends of PEG, PEO and Tween 80 with either Eudragit E PO or 
Soluplus. As PVA is one of most widely used polymers in FDM 3D printing, a PVA based 
solid dispersion was used as a benchmark to compare the polymer blend systems to in terms 
processability. The polymer blends exhibited excellent printability and were suitable for 
processing using a commercially available FDM 3D printer. With 10% drug loading, all 
characterization data indicated that the model drug was molecularly dispersed in the matrices. 
During in vitro dissolution testing, it was clear that the disintegration behavior of the 
formulations significantly influenced the rates of drug release. Eudragit EPO based blend 
dispersions showed bulk disintegration; whereas the Soluplus based blends showed the 
‘peeling’ style disintegration of strip-by-strip. The results indicated that interplay of the 
miscibility between excipients in the blends, the solubility of the materials in the dissolution 
media and the degree of fusion between the printed strips during FDM process can be used to 
manipulate the drug release rate of the dispersions. This brings new insight into the design 
principles of controlled release formulations using FDM 3D printing.  
Key words: 
FDM 3D printing, solid dispersions, hot melt extrusion, poorly soluble drugs, polymer blends  
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Abbreviations 
FDM             Fused Deposition Modeling 
3D                 Three Dimensional   
PVA              Polyvinyl Alcohol 
PLA              Polylactide 
PCL              Polycaprolactone 
HPC              Hydroxypropyl Cellulose    
PEG              Polyethylene Glycol 
PEO              Polyethylene Oxide 
DSC              Differential Scanning Calorimetry 
MTDSC        Temperature Modulated Differential Scanning Calorimetry  
ATR-FTIR    Attenuated Total Reflectance Fourier Transform Infrared 
PXRD          Powder X-Ray Diffraction 
SEM             Scanning Electron Microscopy  
HME            Hot Melt Extrusion 
BCS              Biopharmaceutics Classification System 
Tg                 Glass Transition Temperature 
TGA             Thermal Gravimetric Analysis  
USP             United State Pharmacopoeia  
APIs             Active Pharmaceutical Ingredients 
UV–VIS       Ultraviolet-Visible 
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Introduction 
An encouraging trend of using 3D printing in pharmaceutical manufacturing has been 
established by the approval of Spritam®, which is the first FDA approved 3D printed oral 
dosage form. This first 3D printed commercial drug product used ZipDose® technology, 
which is a wet power deposition 3D printing method. There is a wide range of 3D printing 
technologies that operate via thermal or solvent evaporation mechanisms. FDM 3D printing 
is a thermal based 3D printing technique and has recently attracted the interest of researchers 
in many fields including pharmaceutical formulations design [1-3], food technology [4], and 
tissue engineering [5]. For pharmaceutical applications, this technique has been identified as 
holding future promise for developing individualized oral medicines [1-3,6-8]. FDM 3D 
printing can play an important role in reducing the complexity of drug regimens through 
incorporation of multiple drugs into a ‘polypill’ type of formulations. It may also allow 
different release profiles of the drug to be obtained through changing the exposed surface 
area or the geometry of the dosage form and through using more than one kind of carrier 
material with different drug release characteristics [7, 8]. Although industrial scale FDM 3D 
printing is used in other sectors, until now its applications in pharmaceutical manufacturing 
have been limited to laboratory scale. One of the significant constraints for the development 
of pharmaceutical FDM 3D printing is the extremely limited number of FDM printable 
materials currently available. In most reported cases, the printing of proposed oral solids were 
performed using mostly PVA, PLA and PCL [7-9]. Only recently, the uses of pharmaceutical 
grade polymers for FDM printing of capsules and coating layers were reported [10]. This 
study presents an approach using polymer blends to overcome this problem and open the 
possibility of using pharmaceutically approved polymers in FDM printing of oral solid 
dosage forms. In addition, this study also demonstrates that the blends can be used to control 
the disintegration and drug release of the FDM printed solid dispersions.   
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FDM 3D printing was originally introduced during the 1980s as a branch of the additive 
manufacturing technology. The key element of FDM printing is the extrusion process, which 
allows the thermally softened material strips to be deposited in a ‘writing’ mode. It 
principally works by converting a pre-designed software digital file coding the 3D object into 
a real object by adding a successive series of layers of molten or semi-liquid modeling 
material. Premade filaments with a specific diameter are needed for feeding into the printer. 
The modeling material in the printing state is pushed through a temperature-controlled 3D 
printing nozzle having certain diameter at a pre-adjusted speed into a temperature controlled 
building platform. Depending on the dimensions of the object, the printer nozzle moves in the 
X-Y plane in a particular pattern (determined by the shape of the object) creating the first 
layer. Successive layers are printed by moving either the nozzle or the platform through the Z 
plane with a distance equivalent to the layer thickness. The temperature of the platform is 
normally less than that of the extrusion head allowing the printed material to solidify between 
each layer [11]. The nature of the current state-of-art FDM printing technique leads to three 
significant barriers to exploiting its application in pharmaceutical solids production: (1) 
premade filaments are required as an additional process step and currently available filament 
extruders are largely single screw extruders which may not be able to provide sufficient 
compounding and mixing between the active ingredients and the excipients. Therefore, some 
researchers have used either a commercially available single screw filament maker or twin 
screw hot melt extrusion to produce the filaments for printing [7-10, 12, 13]. (2) Currently 
there is no effective extrusion element in commercially available FDM 3D printers instead 
they rely on rollers at the top of the printer to push the molten materials to the printer nozzle. 
Rheologically this requires the material used to have a low melt viscosity at the printing 
temperature. (3) The molten materials need to solidify rapidly to allow the rapid deposition 
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and accurate buildup of the 3D object according to the pre-set digital design [11]. This 
requires the printing materials to be highly thermoplastic whereas most pharmaceutical grade 
polymers are not thermoplastic.  
 
The last two limitations of the technology can be overcome by selecting appropriate 
polymers. Polymers such as PVA, PLA and PCL have sufficient thermoplasticity to make 
them suitable for FDM 3D printing. However, many printable grades of these polymers are 
not pharmaceutical grade excipients. In addition use of these few polymers often provides 
little flexibility in tailoring the drug release profiles and limits the application of any delivery 
system produced from them. Recently the addition of plasticizers to improve the 
processability of controlled release polymers such as HPC and Eudragit RL and RS during 
FDM printing has been reported [10, 12]. However, to the best of our knowledge so far there 
is no report on the use of polymer blends to FDM print solid dispersions for the dissolution 
enhancement for poorly soluble drugs.  
 
Formulations fabricated using FDM 3D printing are mostly solid dispersion based 
formulations [7-9,13]. Solid dispersions are widely used formulations for improving the 
dissolution of poorly water-soluble drugs [14, 15]. Molecular dispersions in which the 
crystalline drug is dispersed in the polymeric matrices on a molecular scale have been 
recognized as being highly effective for improving the dissolution and subsequent 
bioavailability of many poorly soluble drugs [16, 17]. This study used a BCS class II drug 
[18], felodipine, as a model poorly soluble drug to develop FDM 3D printable blends made of 
pharmaceutically approved excipients. PVA was used as the benchmark polymer in this study 
because of its excellent thermoplasticity and FDM printability [1, 8]. Eudragit EPO and 
Soluplus both have been widely used in pharmaceutical HME indicating their good 
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thermostability and extrudability. However, they are not FDM printable on their own. They 
were selected as the two model polymers which were compounded with an adjustable 
mixture of PEG /PEO and/or Tween 80. PEG has low melt viscosity and was used to adjust 
the printability of the blends. As a result of its high molecular weight, PEO provides 
mechanical flexibility to the filaments to allow easy feeding into the FDM printer. Tween 80 
was used primarily as a plasticizer in order to lower the processing temperature to safe 
temperatures and to overcome degradation issues for the drug under investigation. The 
secondary functions of PEG, PEO and Tween 80 are associated with their good solubilizing 
properties for poorly water soluble drugs and plasticizing characteristics for solid dispersion 
mixtures [19-21].  
 
Materials and methods 
Materials 
Felodipine, the model drug, with mean particle size of 200 µm was purchased from Afine 
Chemicals Ltd (Hangzhou, China). Polyethylene glycol (PEG) (average MWT = 4000) was 
purchased from Sigma Aldrich (Poole, UK). Polysorbate (Tween® 80) was purchased from 
Acros Organics (Geel, Belgium), Polyethylene Oxide (POLYOX WSR N10 LEO) MWT= 
100,000, Soluplus, Eudragit® EPO and 33-38% partially hydrolysed polyvinyl alcohol (PVA) 
MWT= 18,000-25,000 were kindly donated by Colorcon Ltd. (Dartford, UK), BASF 
(Ludwigshafen, Germany), Evonik industries (Darmstadt, Germany) and Kuraray Co., Ltd.  
(Tokyo, Japan), respectively.  The chemical structures of the materials are listed in 
Supplementary Information Figure S1.  
 
Preparation of placebo and felodipine loaded FDM filaments using HME 
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Placebo and 10% w/w felodipine FDM filaments consisting of three sets of excipient 
mixtures (compositions are shown in Table 1) were prepared using a co-rotating twin-screw 
extruder (Haake MiniLab II Micro Compounder, Thermo Electron, Karlsruhe, Germany). 
The formulations containing Eudragit EPO, Soluplus and PVA as the main matrix materials 
are labelled with the abbreviations of CME, CMS and CMV, respectively. All ingredients 
were accurately weighed and premixed using a mortar and pestle for 2 minutes. For each 
extrusion experiment, 7 g of the premixed blend was fed into the extruder and 3 g was kept 
for the characterization of the physical mixtures. The extrusion was performed at the 
specified extrusion temperature (Table 2) with 5 minutes retention time and 100 rpm screw 
speed. After decreasing the rotation speed of the screws to 25 rpm the extruded soft mass of 
the blends was flushed directly through a metal attachment with a circular die of a diameter 
1.75 mm onto a conveyer belt to produce placebo and 10% w/w felodipine loaded filaments.  
 
Using FDM 3D printing to fabricate solid dispersions  
A MakerBot Replicator II desktop 3D printer (New York, United States) equipped with 2 
thermal extruding nozzles (diameter 400 µm) was used for printing the prepared placebo and 
medicated filaments. The digital file for the selected 3D shape in STL (stereolithography) 
format was designed using Blender software [22] and printed using MakerBot MakerWare™. 
In this study, a model disc shape with dimensions of 12 mm diameter and 0.6 mm thickness 
and was used as a standard shape to compare the characteristics of different mixtures. 
Printing was performed using an extrusion temperature of 150 ˚C without heating the 
platform. The 3D object was printed using standard mode with 0.2 mm layer thickness and 
100% infill. The time required to complete printing each disc was 24.7 ± 0.1 seconds with 
only small weights variation between prints (Supplementary Information Table S1). The 
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images of the produced 3D printed discs with their corresponding filaments are shown in 
Figure 1.  
 
Characterization of FDM 3D printed solid dispersions 
Thermal Gravimetric Analysis (TGA) 
TGA Q5000 (TA Instruments, Newcastle, USA) was used to assess the thermal stability of 
the raw materials to ensure that all formulations were processed below the degradation 
temperature and to test the moisture content of the processed samples. 5-10 mg of each 
sample was loaded into the instrument and a temperature programme of 10 ºC/min was used 
over the temperature range 25-500 ºC. Each sample was tested in duplicate and Universal 
Analysis software was used to analyze the obtained results.  
 
Differential Scanning Calorimetry (DSC) and Temperature Modulated DSC (MTDSC) 
A Q-2000 MTDSC (TA Instruments, Newcastle, USA) equipped with (RC90) cooling unit 
was used to analyze felodipine matrices using standard DSC and MTDSC modes. For 
standard DSC, a temperature program a heating ramp of 10 ºC/min was used. MTDSC 
experiments were also performed using a 2 ºC/min heating rate, 60 sec period and 1 ºC or 
0.318 ºC amplitude (depending on the sample) to detect the glass transition temperature(s) 
(Tg) of the different formulations. Sample weights were 2-3 mg contained in an aluminum 
standard TA crimped pans and lids (TA Instruments, Newcastle, USA). Universal Analysis 
software was used to analyze the obtained results. All analyses were performed with 2-3 
replicates for each sample. 
 
Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) 
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All experiments were conducted using an IFS 66/S FTIR spectrometer (Bruker Optics Ltd, 
Coventry, UK) fitted with a Golden Gate® ATR accessory with temperature controllable top 
plate (Orpington, UK) equipped with diamond internal reflection element. ATR-FTIR spectra, 
in absorbance mode, were obtained using a scanning resolution of 2 cm-1 and 32 scans for 
each sample in the range of wave numbers of 4000-550 cm-1.  All spectra were analyzed 
using OPUS software. 
 
Scanning Electron Microscopy (SEM) 
A JSM 5900LV Field Emission Scanning Electron Microscope (Jeol Ltd, Japan) equipped 
with a tungsten hairpin electron gun was used to study the microstructure of different placebo 
and felodipine loaded filaments and discs. Cross sections of all samples were prepared by 
cutting the samples after dipping them into liquid nitrogen. All samples were attached to 
SEM stubs using double adhesive tape and then coated with gold using a Polaran SC7640 
sputter gold coater (Quorum Technologies, city, country) prior to imaging.  
 
Powder X-Ray diffraction (PXRD) 
A Thermo ARL Xtra X-ray diffractometer (Thermo Scientific, Switzerland) with a copper X-
ray Tube (λ =1.540562 Å) was used for to study the physical form of the drug in the different 
formulations and the possible changes in the nature of the components due to processing. The 
samples were analysed using an X-ray beam with voltage of 45 kV and a current of 40 mA. 
The angular scan range was (5 ˚ < 2θ < 60 ˚) using a step scan mode with step width of 0.01˚ 
and scan speed of 1 sec/step. 
 
X-Ray Micro-Computed tomography (XμCT) 
A SkyScan1172 high-resolution X-ray micro computed tomography (XµCT) scanner 
11 
 
(Bruker-microCT, Kontich, Antwerp, Belgium) was used to 3D visualize the microstructure 
of the most promising blend (Eudragit EPO based filaments and FDM 3D printed discs). 
Placebo and 10% w/w loaded samples were scanned using an aluminium filter to cut-off high 
energy X-rays at an isotropic voxel resolution of 3 µm over a total of 20 min acquisition time 
and a subsequent image reconstruction time of approximately 20 min per sample, using the 
NRecon program (version 1.6.8.0, Bruker-microCT). The collected data were then analysed 
using CTan and CTvol software in which the images for a small section (designated as a 
region of interest ROI) of each sample are converted to binary images followed by 
thresholding areas of different electron densities and represented in 3D models [23]. 
Drug solubility measurements 
The saturated solubilities of felodipine were experimentally measured in the pH 6.8 PBS and 
pH 1.2 HCl dissolution media used in this study. The values were determined by adding an 
excess amount of felodipine powder (50 mg) to 25 ml of each medium. The samples (3 
replicates for each) were equilibrated in a shaking incubator (MaxQ 4000, Thermo Scientific, 
USA) for 48 hours at 37 °C. All measurements were repeated 6 times.  
 
In vitro drug release studies 
The in vitro drug release profiles were measured in dissolution testing apparatus (Caleva 8ST, 
Germany) using the paddle method (USP apparatus 1). A paddle rotation speed of 100 rpm 
and 900 ml of pH 1.2 HCl (simulated gastric fluid without enzymes) or phosphate buffer pH 
6.8 (simulated intestinal fluid without enzymes) at 37±0.5 ˚C were used for all measurements.  
The pure crystalline drug (approximately 5mg in powder form) and disc shaped dispersions 
containing the equivalent of the daily dose (5 mg) of the drug were used in this study. Under 
non-sink conditions, 5ml dissolution samples were withdrawn at pre-determined time 
intervals. The samples were directly filtered through a membrane filter with 0.45 µm pore 
12 
 
size (Minisart NML single use syringe, Sartorius, UK). The filtered sample solutions were 
diluted with equal volume of ethanol. 5ml of fresh pre-warmed (37 ± 5 ˚C) dissolution media 
was added to the dissolution vessel after each sampling. The samples were analysed using a 
UV–VIS spectrophotometer (Perkin-Elmer lambda 35, USA) at 363 nm. All dissolution tests 
were performed under non-sink conditions with no addition of surfactants in the media, in 
order to minimise the effect of polymer-surfactant interactions on the drug release behaviour 
from the formulations. All drug release studies were conducted in triplicate.  
 
Determination of drug loading efficiency  
Accurately weighed drug loaded FDM printed discs of different formulations were dissolved 
in a beaker containing 200 ml of 50:50 simulated gastric fluid pH 1.2 and absolute ethanol. 
The beaker was covered with a parafilm tape to minimize solvent evaporation during 
dissolution. The medium was stirred using magnetic stirrer at room temperature. After 
complete dissolution, 5 ml samples were withdrawn and filtered using 0.45 µm pore size 
(Minisart NML single use syringe, Sartorius, UK). The filtered samples then scanned for their 
content of felodipine using a UV–VIS spectrophotometer (Perkin-Elmer lambda 35, USA) at 
363 nm. The loading efficiency measurements for the loaded discs were carried out in 
triplicate. 
 
Results  
Prediction of excipient-excipient and drug-excipient miscibilities using solubility parameter 
(δ) calculations  
The miscibility between the materials used in the blends can significantly affect the 
processability and the qualities, such as the hardness and friability, of the finished products 
[24]. Therefore, predictions of the material’s miscibility and likelihood of phase separation 
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for the three sets of blend formulation were performed. Hoy and Hoftyzer-Van Krevelen 
group contribution methods were used to carry out the solubility parameter calculations 
(detailed calculation can be found in Supplementary Information) [25, 26]. The average 
values obtained from the two calculations were used for comparison in order to ensure more 
accurate results [26]. The rule of thumb for estimating miscibility reported in literature is a 
difference in solubility parameter (Δδ) of less than 7 (MJ/m3)½ indicates that the substances 
are miscible; a Δδ value more than 10 (MJ/m3)½ predicts unfavourable interaction and 
immiscibility between the components of the blend leading to phase separation. A Δδ value of 
7-10 (MJ/m3)½  indicates partial miscibility of the ingredients [21, 27]. As seen in Table 3, the 
calculated solubility parameters for Soluplus and the processing aid materials, PEG, PEO and 
Tween 80, are nearly identical, indicating excellent miscibility of all excipients in CMS 
placebo. The Δδ value is less than 4 for Eudragit with PEO, PEG and Tween 80 which also 
indicates good miscibility between excipients used in CME dispersions. However, the Δδ 
value of PVA with Tween 80 is greater than 7 suggesting partial miscibility of these two 
excipients for CMV formulations. Based on the ranking of the Δδ values, the highest 
miscibility of felodipine with the individual excipients is expected to be in the order of 
Soluplus ≈ PEG 4000 ≈ PEO ≈ Tween 80> Eudragit EPO > PVA. This leads to the predicted 
the rank of the miscibility of felodipine in FDM printed formulations being CMS > CME > 
CMV. 
 
Processability of polymer blend based solid dispersions by FDM 
Eudragit EPO and Soluplus have been widely reported for the preparation of HME solid 
dispersions for enhancing the dissolution of poorly soluble drugs [28-31]. Although both 
polymers on their own are HME extrudable, neither of them were FDM printable even with 
the addition of drug. After blending with PEG, PEO and Tween 80, both polymers were FDM 
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printable. However, due to the higher melting viscosity and lower Tg of Eudragit than 
Soluplus, a greater quantity of PEG and reduced quantity of Tween 80 were added to the 
CME blends in comparison to CMS blends (Table 1). The PVA used in this study was 33-
38% hydrolysed and the HME filament was brittle and not suitable for FDM printing. 
Therefore, Tween 80 was added to plasticise this material and improve the flexibility of the 
filaments which made feeding of the FDM printer easier.  
 
The PVA based filaments are highly thermoplastic. As seen in Table 2, the low extrusion 
torques during HME indicating low melt viscosity of the materials, but readily formed the 
required shape upon cooling (Figure 1). For Eudragit based blends, the addition of felodipine, 
plasticized the mixtures and reduced the extrusion torque during HME which allowed FDM 
printing. For Soluplus based blends, the plasticization effect of the drug is not significant and 
may be masked by the higher Tween 80 content in these blends in comparison to Eudragit 
based blends. Although both Eudragit and Soluplus based blends gave higher extrusion 
torque during HME, the mixtures were FDM printable. Moreover, no clear deformation of the 
shape at a micron scale can be observed using SEM (Figure 2). The surface roughness at the 
edges of each deposited strips of CMS is slightly higher than CME and CMV. This may be 
attributed to the combination of suitable viscosity for FDM deposition but poor 
thermoplasticity. The edge of each printed strip of the materials can be easily identified. It is 
noted that for all three formulations the road width of each strip is approximately 370 ± 10 
µm instead of 400 µm which is the diameter of the printing nozzle. The uniformity of the 
small shrinkage of the road width of the printed materials indicates the similar thermal flow 
behavior of the three blends.  
 
XμCT was used to study the morphology and internal microstructure of the FDM samples at 
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the hundreds of microns to the mm scale. Representative XμCT results for the placebo and 
10% loaded filaments and FDM printed discs of CME blend show some level of micron scale 
surfaces roughness, which matches the SEM observations (Figure 3). The road width of the 
individual FDM strip also matches those observed in the SEM images. Small air pockets 
distributed inside the FDM printed discs can be seen which is absent in the HME filaments. 
The small air pockets are likely to be introduced during the deposition of each layer of strips. 
It was noted that for both HME filaments and FDM printed discs, some phase separated 
particles with high electron density are observed. It can be confirmed that they are not drug 
particles as they are also present in the placebo filaments and discs. They may be metal 
contamination introduced during the extrusion/3D printing processes or some inorganic 
additives included in the raw polymers [23].  
 
Loading efficiency of FDM printed felodipine solid dispersions 
It was reported in the literature that the drug loading efficiency of the FDM 3D printed 
samples prepared by passive diffusion of the drug from its organic solution into the ready-
made placebo PVA filaments was often lower than the theoretical value by more than 15% 
[8, 32, 33]. Using a high printing temperature also can lead to unsatisfactory loading 
efficiency due to the thermal degradation of the drug [8, 32, 33]. A temperature of 150 ˚C 
was used in this study during the FDM printing. The loading efficiencies of felodipine in the 
3D printed CMS, CME and CMV discs were 95.75± 0.66%, 94.62 ± 0.56% and 86.23 ± 
0.83%, respectively. This suggests that processing the mixtures using HME with subsequent 
FDM 3D printing at a suitable temperature can produce solid dispersions with high loading 
efficiency [34]. In addition, this result also indicates that the 3D printing process at 150 ˚C 
led to no thermal degradation of the active drug which was confirmed by the results obtained 
by TGA (Supplementary Information Figures S2 and S3). The lower loading efficiency for 
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10% CMV than CME and CMS may be attributed to the large particle size of PVA granules 
used during preparation which led to poor mixing with the Tween 80 and the drug.  
 
Physical characterization of the FDM printed solid dispersions 
Thermal transitions for the raw materials used in the various formulations were measured 
using DSC and are summarized in Figure 4a. The Tgs of Eudragit EPO, Soluplus, PVA, and 
Tween 80 were identified at 46.7 ± 1.0, 74.1 ± 0.3, 45.3 ± 0.2, and -63.9 ± 0.2, respectively. 
The melting of other blend excipients including Tween 80 (after crystallization at -44.1 ± 0.6 
˚C), PEG and PEO and the model drug can also be identified at -9.1 ± 0.4, 65.6 ± 0.1, 59.6 ± 
0.2 ˚C and 144.7 ± 0.0 ˚C, respectively. The physical mixtures of the CME and CMS show 
melting of PEG and PEO, but no melting of the model drug (Figure 4b). This is likely to be 
due to the thermal dissolution effect of the crystalline drug in the polymer mixtures [20]. The 
melting of felodipine is evident in the DSC results of the physical mixtures of CMV. This 
confirms the partial miscibility between felodipine and PVA predicted previously. MTDSC 
was used to further investigate the Tg region of the samples. As seen in Figure 5a, the 
MTDSC results of the physical mixtures of CME show no detectable Tg. A Tg at 
approximately -55 ˚C can be detected for the physical mixtures of CMS which probably 
arises from the mixture of PEG/PEO/Tween 80. Two Tgs can be clearly seen at -55.4 ± 0.2 
and 39.4 ± 4.3 ˚C in the MTDSC results of the physical mixtures of CMV blends. As the first 
Tg is higher than the Tg of pure Tween and the second is lower than the Tg of pure PVA, they 
are likely to be the Tgs of Tween-drug and PVA-moisture phases, respectively. These Tg’s 
shift to higher temperature (-51.8 ± 0.3 ˚C and 42.9 ± 4.4.5 ˚C) in the reheating cycle which 
may be caused by the further mixing of Tween 80 and PVA and moisture loss of the main 
PVA phase, respectively (Figure 5c). 
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In FDM printed CME and CMS discs containing 10% felodipine, DSC shows the joint 
melting of crystalline PEG and PEO. The melting enthalpy values of the crystalline PEG-
PEO were similar in CME and CMS. However, it should be mentioned that there was 30% 
w/w PEG-PEO in CME and 25% in CMS. This indicates that a greater amount of the 
crystalline PEG-PEO phase was present in CMS in comparison to CME (Supplementary 
information Table S2). It was also noted that the melting point of the PEG-PEO shifted to 
lower temperatures in comparison to those observed in the results of their physical mixtures.  
The solubilisation of other excipients and felodipine may be responsible for this melting 
depression of the crystalline PEG-PEO phase in the printed dispersions. For the drug loaded 
CME, the theoretical Tg of the blend calculated using Fox equation (Supplementary 
Information Table S3) is -5.2 ˚C. This agrees well with the Tg of the FDM printed CME discs 
measured by MTDSC which is a broad transition at approximately -6 ˚C (Figure 5a). The 
detection of a single Tg is a good indicator of the formation of a molecular dispersion of the 
drug and the excipients in CME. For drug loaded CMS samples, the Tg of Tween 80 
disappeared and no clear joint Tg can be detected by MTDSC (Figure 5b). No drug melting 
was detected in the DSC and MTDSC results of CMV dispersions. Two Tgs are present in the 
MTDSC results of the CMV dispersions (Figure 5c) indicating the phase separation in printed 
CMV dispersions. The Tg of the PVA phase shifts to a lower temperature (25.7 ± 1.3 ˚C) in 
the FDM printed dispersions in comparison to the physical mixture. As the Tg of PVA is 
lower than amorphous felodipine and higher than Tween 80, this may indicate enhanced 
mixing of Tween with PVA after processing. The separate Tg at -51.6 ± 2.7 ˚C can be 
assigned to the Tween rich phase. It is likely that felodipine is molecularly dispersed in both 
PVA-rich and Tween 80-rich phases.  
 
ATR-FTIR and PXRD were used to further confirm the physical states of felodipine in the 
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solid dispersions. As seen in Figure 6 the NH stretching peak of crystalline felodipine form I 
at 3367 cm-1 is visible in the physical mixtures. This peak transforms into a broad peak with 
low intensity in the spectra of the FDM printed CME, CMS and CMV discs. This broadening 
may be caused by a combination of the formulation of molecular dispersion of felodipine and 
the small quantity (less than 3% w/w) of moisture present in the printed discs as shown in the 
TGA results (Supplementary Information Figure S4). A few signature diffraction peaks of the 
crystalline felodipine are present in the PXRD diffraction patterns of the physical mixes for 
the three blends (Figure 7). Because both CME and CMS contain semi-crystalline PEG and 
PEO, the main diffraction peaks of these two polymers can be seen in the PXRD patterns of 
the FDM printed discs. The crystalline drug related peaks completely disappear in all patterns 
of the 10% w/w loaded printed discs. Taking in account of the miscibility prediction of 
felodipine and the excipients, the phase separation of amorphous felodipine is unlikely and 
the results indicate the formation of felodipine molecular dispersions at the detection limit of 
PXRD. These results agree well with the DSC results and confirm felodipine was molecularly 
dispersed in all three matrices. 
 
In vitro disintegration and drug release study of FDM printed felodipine dispersions  
The saturated solubilities of crystalline felodipine in the media were 0.14 ± 0.14 µg/ml and 
0.47 ± 0.08 µg/ml in pH 6.8 PBS and pH 1.2 HCl, respectively. Although felodipine is a 
neural compound, the lower solubility of the crystalline felodipine in pH 6.8 PBS than pH 1.2 
HCl observed may be attributed to the higher salt contents in PBS (with a molarity of 0.19 M) 
than HCl (with a molarity of 0.12 M). The dissolution rates of crystalline felodipine powder 
in both media were extremely slow. After 6-hour dissolution test under non-sink conditions, 
the amounts of dissolved crystalline felodipine did not reach saturated solubilities of the drug 
in both media. A significant enhancement of the dissolution profile of felodipine from CME 
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discs in comparison to the crystalline model drug alone was obtained when pH 1.2 HCl was 
used as the dissolution media (Figure 8a). The rapid release of approximately 84.3% of the 
drug load was achieved within 30 minutes. This dissolution improvement may be attributed 
to the formation of the molecular drug dispersion and the high solubility of Eudragit E PO in 
pH 1.2 HCl. The rapid disintegration of the CME discs can be observed within the first 5 
minutes of the dissolution experiments (Figure 9). Eudragit E PO is insoluble at pH 6.8, thus 
little drug release from the CME was expected. However, a delayed but 100% drug release of 
felodipine from the CME discs in pH 6.8 PBS was obtained (Figure 8b). Less than 8% drug 
release occurred in the first 90 minutes. However, from 90 minutes onwards, a linear zero-
order release profile with 100% drug release by 6 hours was observed. The images of the 
discs during the dissolution in pH 6.8 PBS show the slow bulk erosion and disintegration of 
the discs which was completed by 6 hours (Figure 9). A minor level of swelling of the discs 
prior to the complete disintegration and dissolution was observed.  
 
CMS discs showed significantly slower drug release profile in pH 1.2 HCl than CME discs. 
However, it is interesting to note that some improvement in drug dissolution in comparison to 
the crystalline drug alone was still observed from 1 hour onwards and the release follows a 
linear release pattern. The maximum release of 28% was achieved after 6 hours in vitro 
dissolution. Although Soluplus has been reported to be a water-soluble polymer, the addition 
of the inorganic salts in the dissolution medium can depress the cloud point of the polymer 
and reduce the solubility of the polymer in the media [35]. Figure 10 captures the start of the 
disintegration process of CMS discs between 60 to 90 minutes into the dissolution test. A 
closer examination of the images reveals the sequence of the disintegration of CMS discs into 
segments of printed strips which is significantly different from the disintegration of CME in 
pH 6.8 PBS. Between 60-90 minutes, the individual printed polymer strips at the outer edge 
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of the FDM discs started to unravel into single long strands. There were three printed layers 
stacked together to form the discs, the outer printed layer unravelled first to reveal the middle 
layers. This was followed by further breakdown of the longer polymer strips into smaller 
segments. This unique disintegration process contributed to the increased release of drug and 
led to the observed increase in the amount of drug released from 1 hour onwards (Figure 8a). 
This indicates that the disintegration process may be the limiting step for initiating the drug 
release from CMS in HCl. The linear release profile also suggests that the release kinetics of 
felodipine from disintegrated CMS strips is close to zero-order.  In pH 6.8 PBS, CMS discs 
show no dissolution enhancement of felodipine despite of the formation of the molecular 
dispersions of the drug by HME and FDM 3D printing (Figure 8b). It was noted that no 
disintegration occurred in any FDM printed discs during the period of the dissolution tests in 
pH 6.8 PBS. The increased amount of inorganic salt in the PBS may contribute to further 
limit the solubility of Soluplus in the media. No significant swelling was observed through 
the 6 hours of dissolution and a minimal disintegration started by 6 hours (Figure 10b).  
 
In order to further understand the release behaviour, segments of the CMS samples after 6 
hours dissolution were studied using ATR-FTIR and DSC. The ATR-FTIR results (Figure 
10c) show no changes of the drug and excipient peaks in comparison to the dry freshly 
prepared discs after 6 hours dissolution in both media. This confirms that the drug was still in 
aamorphous dispersion with the polymer matrix. These results are consistent with the 
transparency of the dried matrices and the absence of drug crystals in the SEM data of these 
samples (Supplementary information Figure S5). However, the peaks associated with PEG, 
PEO and Tween 80, such as the peaks between 1500 - 850 cm-1, have shown significant 
changes in peak intensity and shape. DSC detected much smaller PEG/PEO melting peaks in 
the post-dissolution discs in comparison to the fresh dry sample (Figure 10d), indicating the 
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leaching of PEG/PEO during dissolution. The first heating cycle showed an overlapped peak 
of the Tg of Soluplus and dehydration of the matrix. However, the second heating cycle 
revealed the Tg of Soluplus. These results imply that the remaining segments after dissolution 
are largely Soluplus which retains the unreleased drug.  
 
No significant release improvement of felodipine from CMV discs was observed in either pH 
1.2 HCl or pH 6.8 PBS in comparison to the crystalline drug (Figure 8). The PVA used in this 
study was a low hydrolysis grade which led to the poor aqueous solubility of the polymer. In 
addition, the effect of ionic strength of the dissolution medium may also play a role in this 
case, reducing the dissolution of PVA in the media [36]. For both cases a degree of gelling of 
the discs during dissolution can be seen in Figure 11a and b. The gelation of CMV discs can 
be attributed to the hydrogel formation ability of PVA reported in literature [37, 38]. The 
discs in pH 1.2 HCl show significant softening that led to the folding of the wetted discs 
(which appears as reduction in size), whereas there was no change in size of the discs tested 
in pH 6.8 PBS. The ATR-FTIR results of the dried CMV samples are shown in Figure 11c. 
No changes can be observed in comparison to the dry freshly prepared discs indicating that 
there was no change in the state of the drug in the CMV solid dispersions after 6 hours 
exposure in both media. The DSC results of the dried discs after 6 hours dissolution reveal 
the absence of a Tg of Tween 80 which was present in the freshly prepared discs (Figure 11d). 
This indicates the leaching of Tween 80 during dissolution.  
 
Discussion 
Linking phase behavior with FDM printability of the dispersions 
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Polymer blending is a widely used formulation strategy in the polymer and plastic industries 
to improve the processability of materials. This study tackled the FDM printability issues of 
two FDA approved and widely used pharmaceutical polymers, Soluplus and Eudragit EPO, 
by blending the polymers with a mixture of PEG, PEO and Tween 80. Although both 
polymers have wide applications in preparation of pharmaceutical HME dispersions, they are 
not printable by conventional FDM 3D printers due to their high melt viscosity and poor 
fluidity. The addition of the mixture of PEG, PEO, Tween 80 as well as the model drug 
significantly improved the viscosity of the polymers during printing as result these then 
matched the printing performance of the PVA based system that is one of the main matrix 
materials used currently in FDM 3D printing. This improved the thermal mechanical 
properties allowing the felodipine-loaded dispersions to be printed into disc shaped, triple 
layered matrices. A clear understanding of the phase behavior of the printed system is 
extremely important for further interpretation of the mechanism of formulation stabilization 
and drug release. As a result of the large number of ingredients used in the printed discs, 
characterization of the phase behavior of the systems is complex. This study took the 
simplified approach of ranking the miscibilities between excipients in order to gain some 
insight into the phase behavior of the blend matrices and the miscibility of felodipine with 
different polymer blends to allow the prediction of likelihood of the formation of molecular 
dispersions of the drug with polymers. The prediction revealed Soluplus and Eudragit E PO 
were miscible with PEG/PEO and Tween 80; whereas PVA is only partially miscible with 
Tween 80. Therefore the mechanism by which the printability of Soluplus and Eudragit is 
improved by addition of these excipients is probably the combination of improved melt 
viscosity and plasticization of the polymers. Results indicated the formation of a molecular 
dispersion of felodipine at 10% loading in FDM printed CME and CMS dispersions. 
Therefore drug incorporation further contributed to the plasticization of the polymer matrices. 
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The addition of Tween 80 reduced the stiffness of the PVA filaments and eased the printing 
process. The weakening of the stiffness may be attributed to the formation of discontinuous 
Tween 80 phases in PVA dispersions, as the two are partially miscible. The addition of 
felodipine further plasticized the polymer. 
 
Linking phase behavior with in vitro disintegration and dissolution performance 
The phase behavior of the printed discs is important for understanding the differences in the 
drug release rates of the formulations. The slower drug release from the CMS system than 
CME is a result of the combination of lower solubility of Soluplus than Eudragit in the media 
and the physical state of the excipients in the dispersions. Although both formulations were 
confirmed to be molecular dispersions of felodipine, their crystalline PEO/PEG contents are 
different. The higher crystalline PEG-PEO content in the CMS compared to CME may 
contribute to the slower drug release from CMS discs. This is because that the crystalline 
PEG/PEO required a wetting and hydration prior to dissolution; whereas these may not occur 
for the molecularly mixed PEG/PEO in the polymer matrices. The reason for the higher 
crystalline content may be associated with the higher melt viscosity of Eudragit than Soluplus 
as suggested by the HME processing torque values. As HME and FDM printing both were 
performed at temperatures above the melting point of the crystalline PEO and PEG, higher 
melt viscosity of the matrix polymer would be more effective in limiting the diffusion of PEG 
and PEO molecules to form large crystalline domains during recrystallization on cooling 
(post-FDM printing). However despite the fact that PEO is a well-known controlled release 
matrix excipient which hydrates and swells once it is in contact with aqueous media [39-42], 
the limited amount of swelling observed in CME and CMS discs during dissolution, indicated 
that the dissolution of PEO/PEG in the dispersions is the more dominant process in these 
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blends. The intimate mixing between PEG/PEO and Soluplus and Eudragit E PO may 
contribute to this observed behavior.   
 
Another interesting feature of the dissolution behavior of these FDM 3D printed discs is the 
difference in their disintegration behavior, which in the case of CMS in pH 1.2 HCl and CME 
in pH 6.8 PBS led to the ‘switching on’ effect of the drug release (Figure 8). It indicates that 
the disassembly of the bulky 3D object that was fabricated by micron-size polymeric strips 
may be used as a novel mechanism of the drug release performance. Therefore a clear 
understanding of the disintegration behavior of the formulation is vitally important. In the 
literature, the disintegration process of FDM printed 3D matrices is still poorly understood. 
The results of this study revealed the unraveling of the printed strips of CMS formulation and 
bulk erosion behavior of CME discs. The exact mechanism for this difference is not clear, but 
(1) the degree of fusion between the printed strips and layers and (2) the speed of dissolution 
of the matrix polymer may be relevant. As seen in Figure 2, the edges of the printed strips of 
CMS are much rougher than CME discs. This may be an indication of low melt viscosity of 
the materials and rapid solidification of the materials after deposition. This should lead to the 
better-defined interfaces between strips and layers which may contribute to the observed 
‘peeling’ effect of strip by strip during the disintegration of CMS. The higher solubility of 
Eudragit at pH 1.2 than Soluplus is believed to responsible to the rapid disintegration and 
dissolution of CME in pH 1.2. For CMS, the drug release results strongly indicated that 
disintegration is the limiting step for drug release. Following disintegration, controlled 
release of drug following zero-order kinetics was observed. The zero order release of CMS in 
pH 1.2 media may be explained by the small diameter of each strip segment, which 
contributes to the short diffusion path length of the drug molecules. This short path length led 
to the negligible effect of changes in diffusion length during dissolution. In addition, the 
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continuous slow breakdown into shorter segments can provide a constantly increasing release 
surface for the drug molecules and led to the observed zero-order like release profile. This 
brings insight into the potential of controlling the drug release rate via manipulation of the 
disintegration behaviour of the bulky solid formulation. This study has demonstrated that this 
is achievable using FDM printing technology, with careful selection of excipients.  
 
Finally the phase behaviour can also be used to explain why the prevention of drug 
recrystallization in the formulations that have no drug dissolution enhancement (CMS and 
CMV). For CMV, as the solubility study suggested the separation of a Tween 80 rich phase 
and a PVA rich phase, one may expect the leaching of Tween during dissolution, which 
would liberate some drug. However, as extremely limited drug release was observed, it 
indicates that although the leaching of Tween may lead to some drug release, the majority of 
drug is still held as molecular dispersion in PVA matrices. This was confirmed by the DSC 
and ATR-FTIR results of the post-dissolution dried samples. The fact that no significant drug 
crystallisation occurred during the period of dissolution indicates that the polymer to drug 
ratio is efficient in stabilising and preventing crystallisation of the remaining drug in the 
matrices. This also applies to the CMS systems in which no drug recrystallization was 
observed during 6 hours of dissolution.   
 
Conclusion 
This study demonstrated the use of polymer blends to overcome the poor printability of 
pharmaceutical polymers during FDM 3D printing. The solid dispersions of felodipine with 
Eudragit and Soluplus were successfully prepared using FDM printing after blending with the 
process and drug release aids, PEG, PEO and Tween 80. Distinctively different disintegration 
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behaviour of the 3D discs with different polymer blends allowed the manipulation of the rate 
of drug release. The results demonstrated the effect of the complex interplay between the 
miscibility of the excipients in the blends, the solubility of the polymer in the media and the 
formation of interfaces between printed strips during the FDM printing on drug release 
behaviour of the dispersions. This brings new insights into the design principles for 
controlled release formulations manufactured using FDM 3D printing.  
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Table 1. Composition of placebo and 10% w/w felodipine loaded FDM dispersions. 
Mixture Code Felodipine 
% w/w 
Eudragit 
EPO 
% w/w 
Soluplus 
% w/w 
PVA 
% w/w 
Tween 80 
% w/w 
PEG 
4000 
% w/w 
PEO 
WSR 
% w/w 
Placebo CME ----- 55.56 ----- ----- 11.10 16.67 16.67 
10% w/w CME 10 50 ----- ----- 10 15 15 
Placebo CMS ----- ----- 55.56 ----- 16.67 11.10 16.67 
10% w/w CMS 10 ----- 50 ----- 15 10 15 
Placebo CMV ----- ----- ----- 75 25 ----- ----- 
10% w/w CMV 10 ----- ----- 67.5 22.5 ----- ----- 
 
 
Table 2. HME-3D printing processing parameters of placebo and 10% w/w loaded felodipine 
filaments and 3D printed discs.   
Mixture Code HME temp. (˚C) FDM printing temp. 
(˚C) 
Extrusion  
torque  
(N.cm) 
Placebo CME 100 150 24 
10% w/w CME 100 150 18 
Placebo CMS 120 150 7 
10% w/w CMS 120 150 8 
Placebo CMV 130 150 1 
10% w/w CMV 130 150 1 
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Table 3.  Predicted solubility parameters of components of formulation and miscibility of 
felodipine in different excipients and their blends. 
Compound 
Hoy’s δ 
(MJ/m3)½ 
Hoftyzer–Van Krevelen δ 
(MJ/m3)½ 
Average δ 
(MJ/m3)½ 
Felodipine 21.08 20.60 20.84 
Eudragit EPO 18.55 18.80 18.68 
Soluplus 24.34 18.94 21.64 
PVA 28.79 30.53 29.66 
Tween 80 22.71 20.9 21.81 
PEO  21.44 22.00 21.72 
PEG 21.44 22.00 21.72 
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Figure 1. Images of the prepared HME filaments and 3D printed discs. 
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Figure 2. SEM images for 10% w/w felodipine loaded FDM 3D printed discs. CME (a) 
surface and (b) cross-section; CMS (c) surface and (d) cross-section; CMV (e) surface and (f) 
cross-section. The dotted lines indicate the widths of filaments strips after FDM printing.  
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Figure 3. Representative XμCT reconstructed 3D images of CME placebo and 10% w/w 
felodipine loaded CME discs. HME filaments (left) and FDM 3D printed discs (right). The 
phase separate particles are likely to be metal contaminations introduced during HME and 
FDM printing.  
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Figure 4. DSC thermograms illustrating different thermal events for (a) raw materials and (b) 
physical mixtures and FDM 3D printed discs of CME, CMS and CMV. 
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Figure 5. MTDSC thermograms showing the Tg of (a) CME formulations using temperature 
program of 1.0 ˚C amplitude, 60 sec period and 2 ˚C/ min heating rate; (b) CMS and (c) 
CMV mixtures using a heat only temperature program of 0.318 ˚C amplitude, 60 sec period 
and 2 ˚C/ min heating rate. 
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Figure 6. Partial ATR-FTIR spectra of the physical mixtures (PM) and felodipine loaded 
FDM printed discs. The NH stretching peak of crystalline felodipine is highlighted with the 
dashed line.  
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Figure 7. PXRD Diffraction patterns of (a) raw materials and (b) physical mixtures and 10% 
w/w felodipine loaded FDM printed CME, CMS and CMV discs. 
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Figure 8. Felodipine release profile of FDM 3D printed discs using a) pH 1.2 HCl (simulated 
gastric fluid without enzyme) and b) pH 6.8 phosphate buffer saline (PBS).   
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Figure 9. Visual appearances of felodipine loaded FDM printed CME discs during 
dissolution in pH 1.2 HCl and pH 6.8 PBS. The dash circles represent the diameters of 
freshly prepared dry CME discs.  
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Figure 10. Visual appearances of the felodipine loaded FDM printed CMS discs during the 
dissolution tests in (a) pH 1.2 HCl and (b) pH 6.8 PBS; (c) the partial ATR-FTIR spectra and 
(d) DSC thermographs of the discs taken out of the media and dried after 6 hours dissolution. 
The dash circles in (a) and (b) represent the diameters of the dry and freshly prepared CMS 
discs. The dash lines in (c) highlight the felodipine related IR peaks and arrows highlight the 
changes of PEG/PEO related peaks labeled with * before dissolution.  
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Figure 11. Visual appearances of the felodipine loaded FDM printed CMV discs during the 
dissolution tests in (a) pH 1.2 HCl and (b) pH 6.8 PBS; (c) the partial ATR-FTIR spectra and 
(d) DSC thermographs of the discs taken out of the media and dried after 6 hours dissolution. 
The dash circles in (a) and (b) represent the diameters of the dry and freshly prepared CMS 
discs. 
 
